EEMY English Greek
 

ΠΡΑΚΤΙΚΕΣ ΚΑΤΕΥΘΥΝΤΗΡΙΕΣ ΟΔΗΓΙΕΣ ΓΙΑ ΤΗΝ ΥΠΕΡΤΑΣΗ - 2005

ΒΙΒΛΙΟΓΡΑΦΙΑ ΠΡΟΗΓΟΥΜΕΝΗ ΣΕΛΙΔΑ  ΠΕΡΙΕΧΟΜΕΝΑ  ΕΠΟΜΕΝΗ ΣΕΛΙΔΑ
  • 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension. J Hypertens 2003;21:1011-53.
  • Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
  • 2003 World Health Organization-International Society of Hypertension Statement on Management of Hypertension. J Hypertens 2003;21:1983-92.
  • Μουντοκαλάκης Θ, Αχείμαστος Α, Βαρσαμής Ε, Ζαμπούλης Χ, Καρατζάς Ν, Παπαδογιάννης Δ, Στεργίου Γ. Συστάσεις για τη διάγνωση και τη θεραπεία της υπέρτασης από τον κλινικό γιατρό. Πρόγραμμα «Υγεία για τον Πολίτη». Οδηγίες Ορθής Κλινικής Πράξης και Φαρμακοθεραπείας. Υπουργείο Υγείας και Πρόνοιας, 2000.
  • The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. Pediatrics 2004;114;555-76
  • Stergiou GS, Thomopoulou GC, Skeva II, Mountokalakis TD. Prevalence, awareness, treatment, and control of hypertension in Greece. The Didima study. Am J Hypertens 1999;12:959-65.
  • Panagiotakos D, Pitsavos C, Chrysohoou C, Skoumas J, Papadimitriou L, Stefanadis C, Toutouzas P. Status and management of hypertension in Greece: role of the adoption of a Mediterranean diet: the Attica study. J Hypertens 2003;21:1483-9.
  • Collins R, Peto R, MacMahon S, Herbert P, Fieback NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-39.
  • MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
  • He J, Whelton PK. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens 1999;17(suppl 2):S7-S13.
  • Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
  • Conroy R, Pyorala K, Fitzgerald A, Sans S, Menotti A, De Backer G, et al on behalf of the SCORE project group. Prediction of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
  • O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden, et al on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension Recommendations for Conventional, Ambulatory and Home Blood Pressure Measurement. J Hypertens 2003;21:821-48.
  • Stergiou G, Mengden T, Padfield P, Parati G, O.Brien E, on behalf of the Working Group on Blood Pressure Monitoring of the European Society of Hypertension. Self-blood pressure monitoring at home is an important adjunct to clinic measurements in patients with hypertension. Br Med J 2004;329;870-1.
  • dabl® Educational Trust. Devices for blood pressure measurement. http://www.dableducational.org. Assessed January 2005.
  • The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 1997;157:657-67.
  • Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering
    Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
  • Julius S, Kjeldsen S, Weber M, Brunner H R, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 363:2022-31.
  • Staessen J, Wang J, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305-15.
  • Blood Pressure Lowering Treatment Trialists. Effects of different blood-pressure-lowering
    regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
ΠΡΟΗΓΟΥΜΕΝΗ ΣΕΛΙΔΑ  ΠΕΡΙΕΧΟΜΕΝΑ  ΕΠΟΜΕΝΗ ΣΕΛΙΔΑ

ΕΠΙΤΡΟΠΗ ΣΥΝΤΑΞΗΣ ΟΔΗΓΙΩΝ
Γ. Στεργίου, συντονιστής
Α. Αχείμαστος
Ε. Βαρσαμής
Δ. Βλαχάκος
Μ. Ελισάφ
Ν. Καρατζάς
Θ. Μουντοκαλάκης
Δ. Παπαδογιάννης
Κ. Σιαμόπουλος